REFERENCES
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
5. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41.
6. van Lingen AV, Arends TJ, Witjes JA. Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2013;13:1257-68.
7. Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A, Hellenic Genito-Urinary Cancer Group (HCUCG). Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Crit Rev Oncol Hematol 2015;93:36-49.
8. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2014;15:25-41.
9. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med 2013;11:13.
10. Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics 2014;32:1093-104.
11. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M, European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013;64:639-53.
12. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778-92.
13. Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010;57:12-20.
14. van Rhijn BW. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol 2012;30:518-23.
15. Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr Opin Urol 2011;21:420-7.
16. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013;10:13.
17. Ye F, Wang L, Castillo-Martin M, McBride R, Galsky MD, Zhu J, Boffetta P, Zhang DY, Cordon-Cardo C. Biomarkers for bladder cancer management: present and future. Am J Clin Exp Urol 2014;2:1-14.
18. Miremami J, Kyprianou N. The promise of novel molecular markers in bladder cancer. Int J Mol Sci 2014;15:23897-908.
19. Buti S, Ciccarese C, Zanoni D, Santoni M, Modena A, Maines F, Gilli A, Bria E, Brunelli M, Rimanti A, Cascinu S, Ardizzoni A, Tortora G, Massari F. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? Future Oncol 2015;11:107-19.
20. Soloway MS. Bladder cancer: Lack of progress in bladder cancer -what are the obstacles? Nat Rev Urol 2013;10:5-6.
22. Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol 2009;41:1452-62.
23. Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol 2009;34:881-95.
24. Ferris RL, Lotze MT, Leong SP, Hoon DS, Morton DL. Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. Clin Exp Metastasis 2012;29:729-36.
25. Pereira ER, Jones D, Jung K, Padera TP. The lymph node microenvironment and its role in the progression of metastatic cancer. Semin Cell Dev Biol 2015;38:98-105.
27. Holopainen T, Bry M, Alitalo K, Saaristo A. Perspectives on lymphangiogenesis and angiogenesis in cancer. J Surg Oncol 2011;103:484-8.
28. Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang Z, Zhou Q. Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta 2013;1836:273-86.
29. Shibata MA, Morimoto J, Shibata E, Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 2008;15:776-86.
30. Zhang D, Li B, Shi J, Zhao L, Zhang X, Wang C, Hou S, Qian W, Kou G, Wang H, Guo Y. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res 2010;70:2495-503.
31. Eklund L, Bry M, Alitalo K. Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol Oncol 2013;7:259-82.
32. Gacche RN, Meshram RJ. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. Biochim Biophys Acta 2014;1846:161-79.
33. Kim S, Ding W, Zhang L, Tian W, Chen S. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther 2014;7:719-28.
34. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123:3190-200.
35. Maione F, Giraudo E. Tumor angiogenesis: methods to analyze tumor vasculature and vessel normalization in mouse models of cancer. Methods Mol Biol 2015;1267:349-65.
36. Pignot G, Bieche I, Vacher S, Guet C, Vieillefond A, Debre B, Lidereau R, Amsellem-Ouazana D. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol 2009;56:678-88.
37. Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimaraes T, Bento MJ, Lobo F, Pinto S, Lopes C. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 2003;14:1419-24.
38. Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004;36:401-5.
39. Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer. Oncol Rep 2009;21:1495-504.
40. Afonso J, Santos LL, Longatto-Filho A. Bladder cancer - From basic science to robotic surgery. In: Canda A, editor. Angiogenesis, Lymphangiogenesis and Lymphovascular Invasion: Prognostic Impact for Bladder Cancer Patients. Croatia: INTECH; 2012. pp. 87-116.
41. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol 2014;26:305-20.
42. von Hardenberg J, Martini T, Knauer A, Strobel P, Becker A, Herrmann E, Schubert C, Steidler A, Bolenz C. Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder. Urol Oncol 2014;32:54.e9-17.
43. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006;98:1090-3.
44. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1001.
45. Zhou M, He L, Zu X, Zhang H, Zeng H, Qi L. Lymphatic vessel density as a predictor of lymph node metastasis and its relationship with prognosis in urothelial carcinoma of the bladder. BJU Int 2011;107:1930-5.
46. Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 2011;10:36.
47. Zhang HH, Qi F, Shi YR, Miao JG, Zhou M, He W, Chen MF, Li Y, Zu XB, Qi L. RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells. Cancer Biother Radiopharm 2012;27:291-8.
48. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 2010;105:1402-12.
49. von Rundstedt FC, Mata DA, Groshen S, Stein JP, Skinner DG, Stadler WM, Cote RJ, Kryvenko ON, Godoy G, Lerner SP. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 2014; doi: 10.1111/bju.12997.
50. Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015;33:643-50.
51. Bolenz C, Herrmann E, Bastian PJ, Michel MS, Wulfing C, Tiemann A, Buchner A, Stief CG, Fritsche HM, Burger M, Wieland WF, Hofner T, Haferkamp A, Hohenfellner M, Muller SC, Strobel P, Trojan L. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 2010;106:493-9.
52. Algaba F. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr Opin Urol 2006;16:367-71.
53. Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Clinicopathological significance of lymphovascular invasion in urothelial carcinoma. Anal Quant Cytol Histol 2012;34:173-9.
54. Afonso J, Santos LL, Amaro T, Lobo F, Longatto-Filho A. The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion --the prognostic contribution of related molecular markers. Histopathology 2009;55:514-24.
55. Chaudhary R, Bromley M, Clarke NW, Betts CD, Barnard RJ, Ryder WD, Kumar S. Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 1999;19:3479-84.
56. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010;183:1744-50.
57. Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012;13:122-35.
58. Horikawa Y, Kumazawa T, Narita S, Inoue T, Yuasa T, Matsuura S, Nanjo H, Satoh S, Tsuchiya N, Habuchi T. Lymphatic invasion is a prognostic factor for bladder cancer treated with radical cystectomy. Int J Clin Oncol 2007;12:131-6.
59. Ma Y, Hou Y, Liu B, Li X, Yang S, Ma J. Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma. Anat Rec (Hoboken) 2010;293:1847-54.
60. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
61. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004;427:695.
62. Bolenz C, Auer M, Strobel P, Heinzelbecker J, Schubert C, Trojan L. The lymphatic system in clinically localized urothelial carcinoma of the bladder: morphologic characteristics and predictive value. Urol Oncol 2013;31:1606-14.
63. De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: Another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 2011;21:73-9.
64. Bambury RM, Rosenberg JE. Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches. Front Pharmacol 2013;4:3.
65. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
66. Videira PA, Piteira AR, Cabral MG, Martins C, Correia M, Severino P, Gouveia H, Carrascal M, Almeida JF, Trindade H, Santos LL. Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines. Urol Int 2011;86:95-101.
67. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771-80.
68. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 2011;52:497-500.
69. Fechner G, Classen K, Schmidt D, Hauser S, Muller SC. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009;73:665-8.
70. Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012;23:2663-70.
71. Houede N, Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther 2015;145:1-18.
72. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev 2015;41:170-8.
73. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/ mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011;58:1054-63.
74. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Nielsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 2010;116:5517-26.
75. Afonso J, Longatto-Filho A, DA Silva VM, Amaro T, Santos LL. Phospho-mTOR in non-tumour and tumour bladder urothelium: pattern of expression and impact on urothelial bladder cancer patients. Oncol Lett 2014;8:1447-454.
76. cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
78. Hurst DR, Welch DR. Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 2011;286:107-80.
79. Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, Welch DR. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. Cancer Microenviron 2014;7:117-31.
80. Al-Mulla F, Bitar MS, Taqi Z, Yeung K. RKIP: Much more than Raf kinase inhibitory protein. J Cell Physiol 2013;228:1688-702.
81. Yesilkanal AE, Rosner MR. Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer. Crit Rev Oncog 2014;19:447-54.
82. Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev 2012;31:615-20.
83. Lamiman K, Keller JM, Mizokami A, Zhang J, Keller ET. Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types. Crit Rev Oncog 2014;19:455-68.
84. Zaravinos A, Chatziioannou M, Lambrou GI, Boulalas I, Delakas D, Spandidos DA. Implication of RAF and RKIP genes in urinary bladder cancer. Pathol Oncol Res 2011;17:181-90.
85. Afonso J, Longatto-Filho A, Martinho O, Lobo F, Amaro T, Reis RM, Santos LL. Low RKIP expression associates with poor prognosis in bladder cancer patients. Virchows Arch 2013;462:445-53.
86. Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis. For Immunopathol Dis Therap 2013;4:79-92.
87. Bonavida B. RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-kappaB/ Snail/YY1/RKIP resistance-driver loop. Crit Rev Oncog 2014;19:431-45.
88. Phan LM, Yeung SC, Lee MH. Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med 2014;11:1-19.
90. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013;123:3685-92.
91. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012;3:E248.
92. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: Insights from the past decade. Pharmacol Ther 2013;137:318-30.
93. Halestrap AP. The SLC16 gene family - Structure, role and regulation in health and disease. Mol Aspects Med 2013;34:337-49.
94. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000;19:3896-904.
95. Xiong L, Edwards CK 3rd, Zhou L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci 2014;15:17411-41.
96. Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queiros O, Preto A, Casal M. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol 2014;29:1511-24.
97. Zhu C, Pan Y, He B, Wang B, Xu Y, Qu L, Bao Q, Tian F, Wang S. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells. Oncol Rep 2011;25:425-32.
98. Zeng HZ, Qu YQ, Liang AB, Deng AM, Zhang WJ, Xiu B, Wang H. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance. Neoplasma 2011;58:449-54.
99. Huang Z, Wang L, Wang Y, Zhuo Y, Li H, Chen J, Chen W. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells. J Oral Pathol Med 2013;42:541-6.
100. Afonso J, Santos LL, Miranda-Goncalves V, Morais A, Amaro T, Longatto-Filho A, Baltazar F. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol Carcinog 2014; doi: 10.1002/mc.22222.
101. Afonso J, Longatto-Filho A, Baltazar F, Sousa N, Costa FE, Morais A, Amaro T, Lopes C, Santos LL. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. Eur J Surg Oncol 2011;37:811-7.
102. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci U S A 2005;102:16245-50.
103. Xue YJ, Lu Q, Sun ZX. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol 2011;28:1363-72.
104. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhoi BP, Sengelov L, Jensen KM, Orntoft TF. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007;13:4407-14.
105. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-36.
106. Choi JW, Kim Y, Lee JH, Kim YS. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. Urology 2014;84:245.e9-15.
107. Tang X, Guo N, Xu L, Gou X, Mi M. CD147/EMMPRIN: an effective therapeutic target for hepatocellular carcinoma. J Drug Target 2013;21:224-31.
108. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 2014;11:400-10.
109. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5.
110. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model. J Urol 2009;182:2195-203.
111. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006;176:1354-61.
112. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006;12:6663-76.
113. Bassi P, Sacco E, De Marco V, Aragona M, Volpe A. Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis. BJU Int 2007;99:1007-12.
114. Buchner A, May M, Burger M, Bolenz C, Herrmann E, Fritsche HM, Ellinger J, Hofner T, Nuhn P, Gratzke C, Brookman-May S, Melchior S, Peter J, Moritz R, Tilki D, Gilfrich C, Roigas J, Zacharias M, Hohenfellner M, Haferkamp A, Trojan L, Wieland WF, Muller SC, Stief CG, Bastian PJ. Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. Eur J Surg Oncol 2013;39:372-9.
115. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. Eur Urol 2008;54:41-53.
116. Shariat SF, Karakiewicz PI, Godoy G, Lerner SP. Use of nomograms for predictions of outcome in patients with advanced bladder cancer. Ther Adv Urol 2009;1:13-26.
117. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-25.
118. Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Biomarkers in bladder cancer. BJU Int 2010;105:608-13.
119. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183:68-75.
120. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, Shariat SF. Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. Eur Urol 2013;64:465-71.
121. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014;111:3110-5.
122. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25:152-65.
123. Brücher BL, Lyman G, van Hillegersberg R, Pollock RE, Lordick F, Yang HK, Ushijima T, Yeoh KG, Skricka T, Polkowski W, Wallner G, Verwaal V, Garofalo A, D'Ugo D, Roviello F, Steinau HU, Wallace TJ, Daumer M, Maihle N, Reid TJ 3rd, Ducreux M, Kitagawa Y, Knuth A, Zilberstein B, Steele SR, Jamall IS. Imagine a world without cancer. BMC Cancer 2014;14:186.
